Dexcom trial shows continuous glucose monitors improve outcomes across diabetes types

Dexcom reported results from a randomized controlled trial that evaluated its continuous glucose monitoring system in a wide range of people with diabetes. The study compared the CGM device to standard glucose monitoring methods.

The trial found that participants using the CGM achieved better glycemic control, experienced fewer low‑blood‑sugar events, and reported higher satisfaction with their diabetes management. These improvements were observed across both type 1 and type 2 diabetes cohorts.

The positive readout adds to mounting evidence that CGM technology can benefit a broader diabetes population, potentially shaping clinical practice and payer decisions. The newsletter also mentioned updates from Apple’s developer conference and other wearable health devices, but the Dexcom data were the primary focus.